[News1] C&R Research maintains solid clinical performance, driving a steady rise in sales
C&R Research, a Clinical Research Organization (CRO), will achieve sales of 61.9 billion KRW this year, marking a 12.3% increase compared to the previous year. This outlook is based on the strong growth of domestic clinical trial performance and the company’s enhanced capabilities following the recent expansion into multinational trials.
According to a corporate report by an analyst from the Korea Investor Relations Service (KIRS), “The backlog of orders grew from 71.8 billion KRW in 2019 to 149.3 billion KRW last year, showing a high annual growth rate of 20.1%.” The report also noted that “sales grew by 19.3%, and this upward trend is expected to continue.”
C&R Research is a Korea CRO specializing in providing clinical development and related services to pharmaceutical companies and bio-ventures.
Notably, it was analyzed that sales will begin to ramp up this year following FDA and EMA approvals of Phase 3 trials for Rophibio’s ‘Eylea biosimilar’ (a biosimilar drug) in 2022.
Please check out further details by following the link below.
